Cargando…
Safety and Effectiveness of Rosiglitazone in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease
BACKGROUND/PURPOSE: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease ranging in severity from steatosis to cirrhosis. Type 2 diabetes mellitus is a cause of primary NAFLD. Thiazolidinediones have been shown to enhance insulin sensitivity, improve glycemic control in type 2...
Autores principales: | Wang, Chao-Hung, Leung, Ching-Hsiang, Liu, Sung-Chen, Chung, Cheng-Ho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Formosan Medical Association & Elsevier. Published by Elsevier (Singapore) Pte Ltd
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134933/ https://www.ncbi.nlm.nih.gov/pubmed/16959622 http://dx.doi.org/10.1016/S0929-6646(09)60202-3 |
Ejemplares similares
-
Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice
por: Mookkan, Jeyamurugan, et al.
Publicado: (2014) -
Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
por: Lu, Yung-Chuan, et al.
Publicado: (2020) -
Common and Unique Factors and the Bidirectional Relationship Between Chronic Kidney Disease and Nonalcoholic Fatty Liver in Type 2 Diabetes Patients
por: Lee, Yau-Jiunn, et al.
Publicado: (2020) -
Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012) -
Nonalcoholic fatty liver disease and diabetes
por: Bellini, Maria Irene, et al.
Publicado: (2022)